Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK: RWD At Center Of NICE Five-Year Strategy

Executive Summary

NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.

You may also be interested in...



England’s NICE To Find New Chief As Leng Announces Retirement

The top job at the National Institute for Health and Care Excellence has been described as one of the most challenging and potentially controversial roles in British public life.

England’s NICE To Find New Chief As Leng Announces Retirement

The top job at the National Institute for Health and Care Excellence has been described as one of the most challenging and potentially controversial roles in British public life.

UK’s NICE Seeks Feedback On Proposed Improvements To Its Processes

Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.

Related Content

Topics

UsernamePublicRestriction

Register

PS144187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel